Characterization of antibody responses to a Plasmodium falciparum blood-stage antigen induced by a DNA prime/protein boost immunization protocol

Scandinavian Journal of Immunology

Volumn 49, Issue 5, 1999, Pages 506-514

  Haddad, D ^a   Liljeqvist, S ^b   Stahl S ^b   Hansson, M ^b   Perlmann, P ^a   Ahlborg, N ^a   Berzins, K ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DNA VACCINE; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M ANTIBODY; PLASMID DNA; PROTOZOAL VACCINE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOFLUORESCENCE; MALARIA; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; COS CELLS; DNA, PROTOZOAN; FEMALE; GENE EXPRESSION; IMMUNOGLOBULIN G; MALARIA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT FUSION PROTEINS; VACCINATION; VACCINES, DNA;

EID: 0032977631     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1999.00543.x     Document Type: Article

References (48)

1. Engers HD, Godal T. Malaria vaccine development: current status. Parasitol Today 1998;14:56-64.
2. Berzins K, Perlmann P. Malaria vaccines: attacking infected erythrocytes. In: Hoffman SL, ed. Malaria Vaccine Development: a Multi-Immune Response Approach. Washington DC: American Society of Microbiology, 1996:105-43.
3. Wåhlin B, Wahlgren M, Perlmann H et al. Human antibodies to a Mr 155,000 Plasmodium falciparum antigen efficiently inhibit merozoite invasion. Proceedings Natl Acad Sci USA 1984;81:7912-16.
4. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 1990;172:1633-41.
5. Groux H, Perraut R, Garraud O, Poingt JP, Gysin J. Functional characterization of the antibody-mediated protection against blood stages of Plasmodium falciparum in the monkey Saimiri sciureus. Eur J Immunol 1990;20:2317-23.
6. Dubois P, Pereira da Silva L. Towards a vaccine against asexual blood stage infection by Plasmodium falciparum. Res Immunol 1995;146:263-75.
7. Xin-Li P, Toshihiro H. Complement-mediated killing of Plasmodium falciparum erythrocytic schizont with antibodies to the recombinant serine repeat antigen (SERA). Vaccine 1998;16:1299-305.
8. Perlmann H, Berzins K, Wahlgren M et al. Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early stages of Plasmodium falciparum. J Exp Med 1984;159:1686-704.
9. Coppel RL, Cowman AF, Anders RF et al. Immune sera recognize on erythrocytes a Plasmodium falciparum antigen composed of repeated amino acid sequences. Nature 1984;310:789-91.
10. Aikawa M, Torii M, Sjölander A, Berzins K, Perlmann P, Miller LH. Pf155/RESA antigen is localized in dense granules of Plasmodium falciparum merozoites. Exp Parasitol 1990;71:326-9.
11. Troye-Blomberg M, Riley EM, Perlmann H et al. T and B cell responses of Plasmodium falciparum malaria-immune individuals to synthetic peptides corresponding to sequences in different regions of the P. falciparum antigen Pf155/RESA J Immunol 1989;143:3043-8.
12. Lew AM, Langford CJ, Pye D, Edwards S, Corcoran L, Anders RF. Class II restriction in mice to the malaria candidate vaccine ring infected erythrocyte surface (RESA) as synthetic peptides or as expressed in recombinant vaccinia. J Immunol 1989;142:4012-6.
13. Ritu G, Rao DN. Construction of synthetic immunogens: use of T-and B-cell epitopes of CS and RESA proteins of Plasmodium falciparum. Vaccine 1992;10:761-5.
14. Sjölander A, Andersson R, Hansson M, Berzins K, Perlmann P. Genetic restriction and specificity of the immune response in mice to fusion proteins containing repeated sequences of the Plasmodium falciparum antigen Pf155/RESA. Immunology 1995;84:360-6.
15. Haddad D, Liljeqvist S, Kumar S et al. Surface display compared to periplasmic expression of a malarial antigen in Salmonella typhimurium and its implications for immunogenicity. FEMS Immunol Med Microbiol 1995;12:175-85.
16. Berzins K, Perlmann H, Wåhlin B et al. Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf155, react with the native protein and inhibit merozoite invasion. Proc Natl Acad Sci USA 1986;83:1065-9.
17. Berzins K, Perlmann H, Wåhlin B et al. Passive immunization of Aotus monkeys with human antibodies to the Plasmodium falciparum antigen Pf155/RESA. Infect Immun 1991;59:1500-6.
18. Ståhl S, Sjölander A, Hansson M, Nygren P-Å, Uhlén M. A general strategy for polymerazion, assembly and expression of epitope-carrying peptides applied to the Plasmodium falciparum antigen Pf155/RESA. Gene 1990;89:187-93.
19. Sinigaglia F, Guttinger M, Kilgus J et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988;336:778-80.
20. Hultman T, Ståhl S, Moks T, Uhlén M. Approaches to solid phase DNA sequencing. Nucleos Nucleot 1988;7:629-38.
21. Hultman T, Ståhl S, Hornes E, Uhlén M. Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. Nucleic Acids Res 1989;17:4937-46.
22. Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
23. Chapman BS, Thayer RM, Vincent KA, Haigwood NL. Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res 1991;19:3979-86.
24. Haddad D, Liljeqvist S, Ståhl S et al. Comparative study of DNA-based immunization vectors: effect of secretion signals on the antibody responses in mice. FEMS Immunol Med Microbiol 1997;18:193-202.
25. Rüther U. pUR 250 allows rapid chemical sequencing of both DNA strands of its insert. Nucleic Acids Res 1982;10:5765-72.
26. Grodberg J, Dunn JJ. ompT encodes the Escherichia coli outer membrane protease that cleaves T7 RNA polymerase during purification. J Bacteriol 1988;170:1245-53.
27. Nygren P-Å, Eliasson M, Palmcrantz E, Abrahmsén L, Uhlén M. Analysis and use of the serum albumin binding domains of streptococcal protein G. J Mol Recognit 1988;1:69-74.
28. Nilsson B, Moks T, Jansson B et al. A synthetic IgG-binding domain based on staphylococcal protein A. Protein Engineering 1987; 1:107-13.
29. Ståhl S, Sjölander A, Nygren P-Å, Berzins K, Perlmann P, Uhlén M. A dual expression system for the generation, analysis and purification of antibodies to a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA. J Immunol Meth 1989;124:43-52.
30. Tam JP. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigen system. Proceedings Natl Acad Sci USA 1988;85:5409-13.
31. Ahlborg N, Iqbal J, Hansson M et al. Immunogens containing sequences from antigen Pf332 induce Plasmodium falciparum-reactive antibodies which inhibit parasite growth but not cytoadherence. Parasite Immunol 1995;17:341-52.
32. Haddad D, Liljeqvist S, Ståhl S, Perlmann P, Berzins K, Ahlborg N. Differential induction of immunoglobulin G subclasses by immunization with DNA vectors containing or lacking a signal sequence. Immunol Letters 1998;61:201-4.
33. Sjölander A, Nygren PÅ, Ståhl S et al. The serum albumin-binding region of streptococcal protein G. A bacterial fusion partner with carrier-related properties. J Immunol Meth 1997;201:115-23.
34. Davis HL. DNA-based vaccination against hepatitis B virus. Adv Drug Delivery Rev 1996;21:33-47.
35. Okuda K, Xin K-Q, Takashi T et al. DNA vaccination followed by macromolecular multicomponent peptide vaccination against HIV-1 induces strong antigen specific immunity. Vaccine 1997;15:1049-56.
36. Fuller D, Corb MM, Barnett S, Steimer K, Haynes J. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine 1997;15:924-6.
37. Deck RR, Corrille MD, Donelly JJ, Liu MA, Ulmer J. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine. Vaccine 1997;15:71-8.
38. Gupta RK, Siber GR. Adjuvants for human vaccines: current status, problems and future prospects. Vaccine 1995;13:1263-76.
39. Kenney JS, Hughes BW, Masada MP, Allison AC. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J Immunol Meth 1989;121:157-66.
40. Roman M, Martin-Orozco E, Goodman JS et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nature Med 1997;3:849-54.
41. Leclerc L, Deriaud E, Rojas M, Wahlen RG. The preferential induction of a Th1 immune response by DNA-based immunization is mediated by the immunostimulatory effect of plasmid DNA. Cellular Immunol 1997;179:97-106.
42. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol 1997; 158:3635-9.
43. Roeffen W, Geeraedts F, Eling W et al. Transmission blockade of Plasmodium falciparum malaria by anti-Pfs230-specific antibodies is isotype dependent. Infect Immun 1995;63:467-71.
44. Chaba B, Kumar P, Haq W et al. Influence of immunoadjuvants and a promiscuous T-cell determinant on the immunogenicity of RESA peptide antigen of P. falciparum. Int J Immunopharmacol 1998;20:259-73.
45. Sharma P, Kumar A, Suchitra B, Sabhnani L, Rao DN. Co-dominant and reciprocal T-helper cell activity of epitopic sequences and formation of junctional B-cell determinants in synthetic T:B chimeric immunogens. Vaccine 1993;11:1321-6.
46. Herrera M, Rosero F, Herrera S et al. Protection against malaria in Aotus monkeys immunized with a recombinant blood-stage antigen fused to a universal T-cell epitope: correlation of serum gamma interferon levels with protection. Infect Immun 1992;60:154-8.
47. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med 1998;4:397-402.
48. Sedegah M, Jones T, Kaur M et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of a malaria DNA vaccine. Proceedings Natl Acad Sci USA 1998; 95:7648-53.